Page last updated: 2024-12-06

sematilide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Sematilide is a selective blocker of the rapidly inactivating potassium current, I(Kr), which is responsible for the repolarization phase of the cardiac action potential. It has been investigated for its potential therapeutic use in treating atrial fibrillation, a common heart rhythm disorder. However, sematilide was withdrawn from clinical trials due to concerns about its potential to cause a rare but serious side effect, torsades de pointes, a life-threatening heart rhythm abnormality. The compound is still studied for its potential in other areas, such as neuroprotection, where it has shown promise in preventing neuronal damage caused by stroke.'

sematilide: RN refers to HCl; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID58505
CHEMBL ID95804
SCHEMBL ID161098
MeSH IDM0173690
PubMed CID58504
CHEMBL ID553757
SCHEMBL ID122585
MeSH IDM0173690

Synonyms (75)

Synonym
CHEMBL95804
sematilide
101526-83-4
0nhb13in3r ,
unii-0nhb13in3r
sematilide [inn]
sematilide [mi]
sematilide [who-dd]
benzamide, n-(2-(diethylamino)ethyl)-4-((methylsulfonyl)amino)-
SCHEMBL161098
DTXSID0058720
AKOS016690547
n-(diethylaminoethyl)-4-methylsulfoaminobenzamide
n-[2-(diethylamino)ethyl]-4-(methanesulfonamido)benzamide;n-[2-(diethylamino)ethyl]-4-(methanesulfonamido)benzamide
n-(2-(diethylamino)ethyl)-4-(methylsulfonamido)benzamide
FT-0760802
ru-752;ru 752;ru752; ck-1752; ck1752; ck 1752
BCP26212
n-[2-(diethylamino)ethyl]-4-(methanesulfonamido)benzamide
HY-101436
bdbm50228547
Q7449133
SDCCGSBI-0633733.P001
NCGC00186049-02
CS-0021329
3h-1,2,4-triazole-3-thione,5-ethyl-1,2-dihydro-(9ci)
sematilide hydrochloride
zk-110516
ck-1752a
D04955
sematilide hydrochloride (usan)
101526-62-9
sematilide hydrochloride [usan]
benzamide, n-(2-(diethylamino)ethyl)-4-((methylsulfonyl)amino)-, monohydrochloride
sematilide monohydrochloride
n-(2-(diethylamino)ethyl)-p-methanesulfonamidobenzamide monohydrochloride
ck-1752
ck 1752a
n-(2-(diethylamino)ethyl)-4-((methylsulfonyl)amino)benzamide monohydrochloride
NCGC00186049-01
n-(2-diethylaminoethyl)-4-(methanesulfonamido)benzamide hydrochloride
CHEMBL553757
sematilide hcl
1b8mc21zi2 ,
unii-1b8mc21zi2
tox21_113523
dtxcid1028942
cas-101526-62-9
dtxsid6049016 ,
CV42038300
niosh/cv4203830
n-(2-(diethylamino)ethyl)-p-(methylsulfonamido)benzamide hydrochloride
benzamide, n-(2-(diethylamino)ethyl)-p-(methylsulfonamido)-, hydrochloride
SCHEMBL122585
sematilide monohydrochloride [mi]
sematilide hydrochloride [who-dd]
n-[2-(diethylamino)ethyl]-4-[(methylsulfonyl)amino]benzamide hydrochloride
OKXAJGDKHKNFAX-UHFFFAOYSA-N
benzamide,n-(2-(diethylamino)ethyl)-4-((methylsulfonyl)amino)-,hcl
benzamide, n-[2-(diethylamino)ethyl]-4-[(methylsulfonyl)amino]-, hydrochloride (1:1);benzamide, n-[2-(diethylamino)ethyl]-4-[(methylsulfonyl)amino]-, hydrochloride (1:1)
FT-0719017
101526-62-9 (hcl)
sematilide hcl;ck-1752 hydrochloride; ck-1752a
BCP25510
benzamide,n-(2-(diethylamino)ethyl)-4-((methylsulfonyl)amino)-,monohydrochloride
sematilide (hydrochloride)
HY-101436A
benzamide, n-(2-(diethylamino)ethyl)-4-((methylsulfonyl)amino)-, monoh ydrochloride
CS-0021328
Q27252191
n-(2-(diethylamino)ethyl)-4-(methylsulfonamido)benzamide hydrochloride
n-[2-(diethylamino)ethyl]-4-(methanesulfonamido)benzamide;hydrochloride
MS-25405
AKOS037515518
BEA52662

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" The pharmacokinetic data analysis used a compartment model independent approach."( Pharmacokinetics of sematilide in renal failure.
Dandekar, KA; Gehr, TW; Hinderling, PH; Ripley, E; Shi, J; Sica, DA, 1996
)
0.29
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35

Bioavailability

ExcerptReferenceRelevance
"Oral bioavailability (F) is a product of fraction absorbed (Fa), fraction escaping gut-wall elimination (Fg), and fraction escaping hepatic elimination (Fh)."( Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV, 2010
)
0.36
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
"The frequency-dependent electrophysiologic effects of sematilide (n = 11) and amiodarone (n = 22) were determined at (1) drug-free baseline, (2) during steady-state (> 48 hours) dosing with sematilide (455 +/- 5 mg/d [mean +/- SEM]) or after 10."( The effects of beta-adrenergic stimulation on the frequency-dependent electrophysiologic actions of amiodarone and sematilide in humans.
Follmer, C; Godfrey, R; Pruitt, C; Sager, PT; Uppal, P, 1994
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (5)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Bile salt export pumpHomo sapiens (human)IC50 (µMol)1,000.00000.11007.190310.0000AID1449628
Beta-2 adrenergic receptorHomo sapiens (human)IC50 (µMol)7,000.00000.00020.93267.2000AID41153
Beta-1 adrenergic receptorHomo sapiens (human)IC50 (µMol)7,000.00000.00021.46819.0000AID41153
Beta-3 adrenergic receptorHomo sapiens (human)IC50 (µMol)7,000.00000.00233.24158.0600AID41153
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
POU domain, class 2, transcription factor 1Homo sapiens (human)Km102.00002.10005.39008.6000AID1769498
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (67)

Processvia Protein(s)Taxonomy
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
diet induced thermogenesisBeta-2 adrenergic receptorHomo sapiens (human)
regulation of sodium ion transportBeta-2 adrenergic receptorHomo sapiens (human)
transcription by RNA polymerase IIBeta-2 adrenergic receptorHomo sapiens (human)
receptor-mediated endocytosisBeta-2 adrenergic receptorHomo sapiens (human)
smooth muscle contractionBeta-2 adrenergic receptorHomo sapiens (human)
cell surface receptor signaling pathwayBeta-2 adrenergic receptorHomo sapiens (human)
activation of transmembrane receptor protein tyrosine kinase activityBeta-2 adrenergic receptorHomo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayBeta-2 adrenergic receptorHomo sapiens (human)
endosome to lysosome transportBeta-2 adrenergic receptorHomo sapiens (human)
response to coldBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of protein kinase A signalingBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of bone mineralizationBeta-2 adrenergic receptorHomo sapiens (human)
heat generationBeta-2 adrenergic receptorHomo sapiens (human)
negative regulation of multicellular organism growthBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeBeta-2 adrenergic receptorHomo sapiens (human)
bone resorptionBeta-2 adrenergic receptorHomo sapiens (human)
negative regulation of G protein-coupled receptor signaling pathwayBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIBeta-2 adrenergic receptorHomo sapiens (human)
negative regulation of smooth muscle contractionBeta-2 adrenergic receptorHomo sapiens (human)
brown fat cell differentiationBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of mini excitatory postsynaptic potentialBeta-2 adrenergic receptorHomo sapiens (human)
adrenergic receptor signaling pathwayBeta-2 adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of protein serine/threonine kinase activityBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of cold-induced thermogenesisBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of autophagosome maturationBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of lipophagyBeta-2 adrenergic receptorHomo sapiens (human)
cellular response to amyloid-betaBeta-2 adrenergic receptorHomo sapiens (human)
response to psychosocial stressBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of cAMP-dependent protein kinase activityBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of AMPA receptor activityBeta-2 adrenergic receptorHomo sapiens (human)
norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressureBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of heart rate by epinephrine-norepinephrineBeta-1 adrenergic receptorHomo sapiens (human)
positive regulation of the force of heart contraction by epinephrine-norepinephrineBeta-1 adrenergic receptorHomo sapiens (human)
diet induced thermogenesisBeta-1 adrenergic receptorHomo sapiens (human)
response to coldBeta-1 adrenergic receptorHomo sapiens (human)
heat generationBeta-1 adrenergic receptorHomo sapiens (human)
negative regulation of multicellular organism growthBeta-1 adrenergic receptorHomo sapiens (human)
fear responseBeta-1 adrenergic receptorHomo sapiens (human)
regulation of circadian sleep/wake cycle, sleepBeta-1 adrenergic receptorHomo sapiens (human)
brown fat cell differentiationBeta-1 adrenergic receptorHomo sapiens (human)
regulation of postsynaptic membrane potentialBeta-1 adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayBeta-1 adrenergic receptorHomo sapiens (human)
positive regulation of cold-induced thermogenesisBeta-1 adrenergic receptorHomo sapiens (human)
norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressureBeta-1 adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeBeta-1 adrenergic receptorHomo sapiens (human)
receptor-mediated endocytosisBeta-3 adrenergic receptorHomo sapiens (human)
negative regulation of G protein-coupled receptor signaling pathwayBeta-3 adrenergic receptorHomo sapiens (human)
diet induced thermogenesisBeta-3 adrenergic receptorHomo sapiens (human)
carbohydrate metabolic processBeta-3 adrenergic receptorHomo sapiens (human)
generation of precursor metabolites and energyBeta-3 adrenergic receptorHomo sapiens (human)
energy reserve metabolic processBeta-3 adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerBeta-3 adrenergic receptorHomo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayBeta-3 adrenergic receptorHomo sapiens (human)
response to coldBeta-3 adrenergic receptorHomo sapiens (human)
heat generationBeta-3 adrenergic receptorHomo sapiens (human)
negative regulation of multicellular organism growthBeta-3 adrenergic receptorHomo sapiens (human)
eating behaviorBeta-3 adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeBeta-3 adrenergic receptorHomo sapiens (human)
brown fat cell differentiationBeta-3 adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayBeta-3 adrenergic receptorHomo sapiens (human)
positive regulation of cold-induced thermogenesisBeta-3 adrenergic receptorHomo sapiens (human)
norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressureBeta-3 adrenergic receptorHomo sapiens (human)
negative regulation of DNA-templated transcriptionPOU domain, class 2, transcription factor 1Homo sapiens (human)
negative regulation of DNA-templated transcriptionPOU domain, class 2, transcription factor 1Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIPOU domain, class 2, transcription factor 1Homo sapiens (human)
positive regulation of miRNA transcriptionPOU domain, class 2, transcription factor 1Homo sapiens (human)
regulation of transcription by RNA polymerase IIPOU domain, class 2, transcription factor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (31)

Processvia Protein(s)Taxonomy
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
amyloid-beta bindingBeta-2 adrenergic receptorHomo sapiens (human)
beta2-adrenergic receptor activityBeta-2 adrenergic receptorHomo sapiens (human)
protein bindingBeta-2 adrenergic receptorHomo sapiens (human)
adenylate cyclase bindingBeta-2 adrenergic receptorHomo sapiens (human)
potassium channel regulator activityBeta-2 adrenergic receptorHomo sapiens (human)
identical protein bindingBeta-2 adrenergic receptorHomo sapiens (human)
protein homodimerization activityBeta-2 adrenergic receptorHomo sapiens (human)
protein-containing complex bindingBeta-2 adrenergic receptorHomo sapiens (human)
norepinephrine bindingBeta-2 adrenergic receptorHomo sapiens (human)
beta-adrenergic receptor activityBeta-1 adrenergic receptorHomo sapiens (human)
beta1-adrenergic receptor activityBeta-1 adrenergic receptorHomo sapiens (human)
protein bindingBeta-1 adrenergic receptorHomo sapiens (human)
PDZ domain bindingBeta-1 adrenergic receptorHomo sapiens (human)
alpha-2A adrenergic receptor bindingBeta-1 adrenergic receptorHomo sapiens (human)
protein heterodimerization activityBeta-1 adrenergic receptorHomo sapiens (human)
G protein-coupled neurotransmitter receptor activity involved in regulation of postsynaptic membrane potentialBeta-1 adrenergic receptorHomo sapiens (human)
norepinephrine bindingBeta-3 adrenergic receptorHomo sapiens (human)
beta-adrenergic receptor activityBeta-3 adrenergic receptorHomo sapiens (human)
protein bindingBeta-3 adrenergic receptorHomo sapiens (human)
beta3-adrenergic receptor activityBeta-3 adrenergic receptorHomo sapiens (human)
beta-3 adrenergic receptor bindingBeta-3 adrenergic receptorHomo sapiens (human)
protein homodimerization activityBeta-3 adrenergic receptorHomo sapiens (human)
epinephrine bindingBeta-3 adrenergic receptorHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingPOU domain, class 2, transcription factor 1Homo sapiens (human)
RNA polymerase II core promoter sequence-specific DNA bindingPOU domain, class 2, transcription factor 1Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificPOU domain, class 2, transcription factor 1Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificPOU domain, class 2, transcription factor 1Homo sapiens (human)
DNA bindingPOU domain, class 2, transcription factor 1Homo sapiens (human)
protein bindingPOU domain, class 2, transcription factor 1Homo sapiens (human)
sequence-specific DNA bindingPOU domain, class 2, transcription factor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (26)

Processvia Protein(s)Taxonomy
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
nucleusBeta-2 adrenergic receptorHomo sapiens (human)
lysosomeBeta-2 adrenergic receptorHomo sapiens (human)
endosomeBeta-2 adrenergic receptorHomo sapiens (human)
early endosomeBeta-2 adrenergic receptorHomo sapiens (human)
Golgi apparatusBeta-2 adrenergic receptorHomo sapiens (human)
plasma membraneBeta-2 adrenergic receptorHomo sapiens (human)
endosome membraneBeta-2 adrenergic receptorHomo sapiens (human)
membraneBeta-2 adrenergic receptorHomo sapiens (human)
apical plasma membraneBeta-2 adrenergic receptorHomo sapiens (human)
clathrin-coated endocytic vesicle membraneBeta-2 adrenergic receptorHomo sapiens (human)
neuronal dense core vesicleBeta-2 adrenergic receptorHomo sapiens (human)
receptor complexBeta-2 adrenergic receptorHomo sapiens (human)
plasma membraneBeta-2 adrenergic receptorHomo sapiens (human)
early endosomeBeta-1 adrenergic receptorHomo sapiens (human)
plasma membraneBeta-1 adrenergic receptorHomo sapiens (human)
Schaffer collateral - CA1 synapseBeta-1 adrenergic receptorHomo sapiens (human)
neuronal dense core vesicleBeta-1 adrenergic receptorHomo sapiens (human)
plasma membraneBeta-1 adrenergic receptorHomo sapiens (human)
plasma membraneBeta-3 adrenergic receptorHomo sapiens (human)
receptor complexBeta-3 adrenergic receptorHomo sapiens (human)
plasma membraneBeta-3 adrenergic receptorHomo sapiens (human)
nucleusPOU domain, class 2, transcription factor 1Homo sapiens (human)
nucleoplasmPOU domain, class 2, transcription factor 1Homo sapiens (human)
endoplasmic reticulumPOU domain, class 2, transcription factor 1Homo sapiens (human)
intracellular membrane-bounded organellePOU domain, class 2, transcription factor 1Homo sapiens (human)
chromatinPOU domain, class 2, transcription factor 1Homo sapiens (human)
RNA polymerase II transcription regulator complexPOU domain, class 2, transcription factor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (81)

Assay IDTitleYearJournalArticle
AID56839The percentage change of the duration of action potential at 75% repolarization was measured before and after the administration at 3.0 ug/mL1992Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18
Synthesis and pharmacological studies of N-substituted 6-[(2-aminoethyl)amino]-1,3-dimethyl-2,4(1H,3H)-pyrimidinediones, novel class III antiarrhythmic agents.
AID444056Fraction escaping gut-wall elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1769498Substrate activity at human OCT1 expressed in HEK293 cells assessed as increase in compound uptake by measuring Km incubated for 2 mins by LC-MS/MS analysis2021Journal of medicinal chemistry, 03-11, Volume: 64, Issue:5
Identification of Novel High-Affinity Substrates of OCT1 Using Machine Learning-Guided Virtual Screening and Experimental Validation.
AID444058Volume of distribution at steady state in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID22280Percent change from control value for Vmax at 0.1 uM of the compound.1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Synthesis and cardiac electrophysiological activity of aryl-substituted derivatives of the class III antiarrhythmic agent sematilide. Potential class I/III agents.
AID425653Renal clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID425652Total body clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID205279Percentage inhibition of specific binding of [3H]batrachotoxin [3H]BTX) in sodium channel from cardiac myocytes at 10 uM1993Journal of medicinal chemistry, Oct-29, Volume: 36, Issue:22
4,5-Dihydro-1-phenyl-1H-2,4-benzodiazepines: novel antiarrhythmic agents.
AID444051Total clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID22283Percent change from control value for Vmax at 10 uM of the compound.1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Synthesis and cardiac electrophysiological activity of aryl-substituted derivatives of the class III antiarrhythmic agent sematilide. Potential class I/III agents.
AID162803Duration of action potential in vitro against Canine Purkinje fibers; at 1 uM concentration1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Synthesis and cardiac electrophysiological activity of aryl-substituted derivatives of the class III antiarrhythmic agent sematilide. Potential class I/III agents.
AID444052Hepatic clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID162799Duration of action potential in vitro against Canine Purkinje fibers, at 100 uM concentration.1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Synthesis and cardiac electrophysiological activity of aryl-substituted derivatives of the class III antiarrhythmic agent sematilide. Potential class I/III agents.
AID162801Duration of action potential in vitro against Canine Purkinje fibers, at 30 uM concentration.1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Synthesis and cardiac electrophysiological activity of aryl-substituted derivatives of the class III antiarrhythmic agent sematilide. Potential class I/III agents.
AID162800Duration of action potential in vitro against Canine Purkinje fibers, at 10 uM concentration.1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Synthesis and cardiac electrophysiological activity of aryl-substituted derivatives of the class III antiarrhythmic agent sematilide. Potential class I/III agents.
AID444050Fraction unbound in human plasma2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID444054Oral bioavailability in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID74038Effective dose in vivo for cardiac refractoriness (ERP) using paced guinea pig model1993Journal of medicinal chemistry, Oct-29, Volume: 36, Issue:22
4,5-Dihydro-1-phenyl-1H-2,4-benzodiazepines: novel antiarrhythmic agents.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1769499Substrate activity at human OCT1 expressed in HEK293 cells assessed as increase in compound uptake by measuring Vmax incubated for 2 mins by LC-MS/MS analysis2021Journal of medicinal chemistry, 03-11, Volume: 64, Issue:5
Identification of Novel High-Affinity Substrates of OCT1 Using Machine Learning-Guided Virtual Screening and Experimental Validation.
AID56837The percentage change of the duration of action potential at 75% repolarization was measured before and after the administration at 1.0 ug/mL1992Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18
Synthesis and pharmacological studies of N-substituted 6-[(2-aminoethyl)amino]-1,3-dimethyl-2,4(1H,3H)-pyrimidinediones, novel class III antiarrhythmic agents.
AID1769501Ratio of drug uptake in human OCT1 expressing HEK293 cells at 2.5 uM to drug uptake in empty vector transfected human HEK293 cells at 2.5 uM2021Journal of medicinal chemistry, 03-11, Volume: 64, Issue:5
Identification of Novel High-Affinity Substrates of OCT1 Using Machine Learning-Guided Virtual Screening and Experimental Validation.
AID22281Percent change from control value for Vmax at 100 uM of the compound.1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Synthesis and cardiac electrophysiological activity of aryl-substituted derivatives of the class III antiarrhythmic agent sematilide. Potential class I/III agents.
AID22288Percent change from control value for Vmax at 30 uM of the compound; no data1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Synthesis and cardiac electrophysiological activity of aryl-substituted derivatives of the class III antiarrhythmic agent sematilide. Potential class I/III agents.
AID78122In vivo index of cardiac contractility using paced guinea pig model1993Journal of medicinal chemistry, Oct-29, Volume: 36, Issue:22
4,5-Dihydro-1-phenyl-1H-2,4-benzodiazepines: novel antiarrhythmic agents.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID63502Concentration that causes a 20% increase in APD95 (action potential duration at 95% repolarization) from control value in anesthetized dogs1990Journal of medicinal chemistry, Oct, Volume: 33, Issue:10
Synthesis of novel (aryloxy)propanolamines and related compounds possessing both class II and class III antiarrhythmic activity.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID161144Percentage inhibition of specific binding of [3H]dofetilide (UK-68,798) from cardiac myocytes with blockade of delayed rectifier K+ channel1993Journal of medicinal chemistry, Oct-29, Volume: 36, Issue:22
4,5-Dihydro-1-phenyl-1H-2,4-benzodiazepines: novel antiarrhythmic agents.
AID1769500Substrate activity at human OCT1 expressed in HEK293 cells assessed as increase in compound uptake by measuring intrinsic clearance incubated for 2 mins by LC-MS/MS analysis2021Journal of medicinal chemistry, 03-11, Volume: 64, Issue:5
Identification of Novel High-Affinity Substrates of OCT1 Using Machine Learning-Guided Virtual Screening and Experimental Validation.
AID444055Fraction absorbed in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1449628Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID22290Percent change from control value for Vmax at 3 uM of the compound; no data1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Synthesis and cardiac electrophysiological activity of aryl-substituted derivatives of the class III antiarrhythmic agent sematilide. Potential class I/III agents.
AID444053Renal clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID162809Duration of action potential was determined in vitro in Canine Purkinje fibers at 0.1 uM concentration.1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Synthesis and cardiac electrophysiological activity of aryl-substituted derivatives of the class III antiarrhythmic agent sematilide. Potential class I/III agents.
AID444057Fraction escaping hepatic elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID22285Percent change from control value for Vmax at 1 uM of the compound.1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Synthesis and cardiac electrophysiological activity of aryl-substituted derivatives of the class III antiarrhythmic agent sematilide. Potential class I/III agents.
AID59321Antiarrhythmic efficacy in vivo against PES model1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Synthesis and cardiac electrophysiological activity of aryl-substituted derivatives of the class III antiarrhythmic agent sematilide. Potential class I/III agents.
AID41153Tested for Beta adrenergic receptor binding inhibition from canine ventricular tissue, using [3H]dihydroalprenolol as the radioligand in anesthetized dogs1990Journal of medicinal chemistry, Oct, Volume: 33, Issue:10
Synthesis of novel (aryloxy)propanolamines and related compounds possessing both class II and class III antiarrhythmic activity.
AID63506Concentration at which maximum change in APA95 was observed from control value in anesthetized dogs; The maximum observed change APD95 from control value and concentration at 100 uM when this occurred1990Journal of medicinal chemistry, Oct, Volume: 33, Issue:10
Synthesis of novel (aryloxy)propanolamines and related compounds possessing both class II and class III antiarrhythmic activity.
AID162802Duration of action potential in vitro against Canine Purkinje fibers, at 3 uM concentration.1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Synthesis and cardiac electrophysiological activity of aryl-substituted derivatives of the class III antiarrhythmic agent sematilide. Potential class I/III agents.
AID60495Efficacy in blocking sustained ventricular tachycardia (rate>250 bpm) elicited by programmed electrical stimulation in conscious dogs. Administered orally at a dose of 2.5 mg/kg after iv administration; no. of successful exp / total no. of exp = 5 /61987Journal of medicinal chemistry, May, Volume: 30, Issue:5
Rational design of 4-[(methylsulfonyl)amino]benzamides as class III antiarrhythmic agents.
AID61930Effective dose with the number of animals in PES efficacy model of conscious dog1990Journal of medicinal chemistry, Apr, Volume: 33, Issue:4
Synthesis and cardiac electrophysiological activity of N-substituted-4-(1H-imidazol-1-yl)benzamides--new selective class III agents.
AID26644pKa1 was determined1987Journal of medicinal chemistry, May, Volume: 30, Issue:5
Rational design of 4-[(methylsulfonyl)amino]benzamides as class III antiarrhythmic agents.
AID62408Number of animals in which sustained ventricular tachycardia or ventricular fibrillation was not inducible after drug administration among the number of animals tested (9) in PES efficacy model of anesthetized dog1990Journal of medicinal chemistry, Apr, Volume: 33, Issue:4
Synthesis and cardiac electrophysiological activity of N-substituted-4-(1H-imidazol-1-yl)benzamides--new selective class III agents.
AID22292Percent change in the Vmax at a 10 uM concentration of the test compound; Minimal1990Journal of medicinal chemistry, Apr, Volume: 33, Issue:4
Synthesis and cardiac electrophysiological activity of N-substituted-4-(1H-imidazol-1-yl)benzamides--new selective class III agents.
AID26858pKa2 was determined1987Journal of medicinal chemistry, May, Volume: 30, Issue:5
Rational design of 4-[(methylsulfonyl)amino]benzamides as class III antiarrhythmic agents.
AID25675Half life period was determined1987Journal of medicinal chemistry, May, Volume: 30, Issue:5
Rational design of 4-[(methylsulfonyl)amino]benzamides as class III antiarrhythmic agents.
AID60704In vivo electrophysiology was given as change in Function refractory period at 3 mg/kg, iv1990Journal of medicinal chemistry, Apr, Volume: 33, Issue:4
Synthesis and cardiac electrophysiological activity of N-substituted-4-(1H-imidazol-1-yl)benzamides--new selective class III agents.
AID61928Effective dose with the number of animals in PES efficacy model of anesthetized dog1990Journal of medicinal chemistry, Apr, Volume: 33, Issue:4
Synthesis and cardiac electrophysiological activity of N-substituted-4-(1H-imidazol-1-yl)benzamides--new selective class III agents.
AID55777Concentration which caused a 20% increase in AP95 was determined.1990Journal of medicinal chemistry, Apr, Volume: 33, Issue:4
Synthesis and cardiac electrophysiological activity of N-substituted-4-(1H-imidazol-1-yl)benzamides--new selective class III agents.
AID55752Concentration required for 20% increase in action potential duration of canine Purkinje fiber (intracellular electrophysiology) in vitro measured at 95% repolarization was reported. RAnge is between 2.0-11.41987Journal of medicinal chemistry, May, Volume: 30, Issue:5
Rational design of 4-[(methylsulfonyl)amino]benzamides as class III antiarrhythmic agents.
AID60705In vivo electrophysiology was given as change in Function refractory period at 30 mg/kg, id1990Journal of medicinal chemistry, Apr, Volume: 33, Issue:4
Synthesis and cardiac electrophysiological activity of N-substituted-4-(1H-imidazol-1-yl)benzamides--new selective class III agents.
AID24618Maximum observed percent change in Vmax and the concentration at which it was observed was determined at 30 uM; Minimal1990Journal of medicinal chemistry, Apr, Volume: 33, Issue:4
Synthesis and cardiac electrophysiological activity of N-substituted-4-(1H-imidazol-1-yl)benzamides--new selective class III agents.
AID60353Efficacy in blocking sustained ventricular tachycardia (rate>250 bpm) elicited by programmed electrical stimulation in 4 anesthetized dogs after iv administration of dose 1 mg/kg; no. of successful exp / total no. of exp = 4/41987Journal of medicinal chemistry, May, Volume: 30, Issue:5
Rational design of 4-[(methylsulfonyl)amino]benzamides as class III antiarrhythmic agents.
AID55770Concentration required for 20% increase in the functional refractory period of canine ventricular muscle (extracellular electrophysiology) in vitro was reported. Range is between 9-351987Journal of medicinal chemistry, May, Volume: 30, Issue:5
Rational design of 4-[(methylsulfonyl)amino]benzamides as class III antiarrhythmic agents.
AID58034Bioavailability after peroral administration (3 mg/kg) in dog was determined; Range 41-98%1987Journal of medicinal chemistry, May, Volume: 30, Issue:5
Rational design of 4-[(methylsulfonyl)amino]benzamides as class III antiarrhythmic agents.
AID24617Maximum observed percent change in Vmax and the concentration at which it was observed was determined at 100 uM; Minimal1990Journal of medicinal chemistry, Apr, Volume: 33, Issue:4
Synthesis and cardiac electrophysiological activity of N-substituted-4-(1H-imidazol-1-yl)benzamides--new selective class III agents.
AID59737Maximum observed percent change in action potential duration (APD) at 95% repolarization at 100 uM using standard microelectrode technique in isolated canine cardiac Purkinje fibers1990Journal of medicinal chemistry, Apr, Volume: 33, Issue:4
Synthesis and cardiac electrophysiological activity of N-substituted-4-(1H-imidazol-1-yl)benzamides--new selective class III agents.
AID61931Effective dose with the number of animals in PES efficacy model of conscious dog; Not effective in one animal1990Journal of medicinal chemistry, Apr, Volume: 33, Issue:4
Synthesis and cardiac electrophysiological activity of N-substituted-4-(1H-imidazol-1-yl)benzamides--new selective class III agents.
AID58665Percent change in heart rate from control at 3 mg/kg, iv1990Journal of medicinal chemistry, Apr, Volume: 33, Issue:4
Synthesis and cardiac electrophysiological activity of N-substituted-4-(1H-imidazol-1-yl)benzamides--new selective class III agents.
AID61929Effective dose with the number of animals in PES efficacy model of anesthetized dog; Not effective in one animal1990Journal of medicinal chemistry, Apr, Volume: 33, Issue:4
Synthesis and cardiac electrophysiological activity of N-substituted-4-(1H-imidazol-1-yl)benzamides--new selective class III agents.
AID58666Percent change in heart rate from control at 30 mg/kg, id1990Journal of medicinal chemistry, Apr, Volume: 33, Issue:4
Synthesis and cardiac electrophysiological activity of N-substituted-4-(1H-imidazol-1-yl)benzamides--new selective class III agents.
AID134236Acute toxicity after intraperitoneal administration in mouse was determined; range 250-300 mg/kg1987Journal of medicinal chemistry, May, Volume: 30, Issue:5
Rational design of 4-[(methylsulfonyl)amino]benzamides as class III antiarrhythmic agents.
AID60703In vivo electrophysiology was given as change in Function refractory period at 10 mg/kg, id1990Journal of medicinal chemistry, Apr, Volume: 33, Issue:4
Synthesis and cardiac electrophysiological activity of N-substituted-4-(1H-imidazol-1-yl)benzamides--new selective class III agents.
AID25642Half life of the electrophysiological effect was evaluated at 3 mg/kg, iv1990Journal of medicinal chemistry, Apr, Volume: 33, Issue:4
Synthesis and cardiac electrophysiological activity of N-substituted-4-(1H-imidazol-1-yl)benzamides--new selective class III agents.
AID62407Number of animals in which sustained ventricular tachycardia or ventricular fibrillation was not inducible after drug administration among the number of animals tested (5) in PES efficacy model of anesthetized dog1990Journal of medicinal chemistry, Apr, Volume: 33, Issue:4
Synthesis and cardiac electrophysiological activity of N-substituted-4-(1H-imidazol-1-yl)benzamides--new selective class III agents.
AID58664Percent change in heart rate from control at 10 mg/kg, id1990Journal of medicinal chemistry, Apr, Volume: 33, Issue:4
Synthesis and cardiac electrophysiological activity of N-substituted-4-(1H-imidazol-1-yl)benzamides--new selective class III agents.
AID61757Percent change in action potential duration at 95% repolarization and 10 uM in isolated canine cardiac Purkinje fibres.1990Journal of medicinal chemistry, Apr, Volume: 33, Issue:4
Synthesis and cardiac electrophysiological activity of N-substituted-4-(1H-imidazol-1-yl)benzamides--new selective class III agents.
AID59739Maximum observed percent change in action potential duration (APD) at 95% repolarization at 30 uM using standard microelectrode technique in isolated canine cardiac Purkinje fibers1990Journal of medicinal chemistry, Apr, Volume: 33, Issue:4
Synthesis and cardiac electrophysiological activity of N-substituted-4-(1H-imidazol-1-yl)benzamides--new selective class III agents.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (49)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (2.04)18.7374
1990's33 (67.35)18.2507
2000's6 (12.24)29.6817
2010's4 (8.16)24.3611
2020's5 (10.20)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 23.86

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index23.86 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index4.42 (4.65)
Search Engine Demand Index23.28 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (23.86)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials6 (14.29%)5.53%
Trials0 (0.00%)5.53%
Reviews1 (2.38%)6.00%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other35 (83.33%)84.16%
Other8 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]